Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Novadaq's Story Continues To Come Along

I don't expect the med-tech sector to match the performance of 2013 this year, but I continue to believe that Novadaq (NASDAQ:NVDQ) will be a market-beater. Novadaq has only just begun to show what its imaging technology can do in terms of clinical results, market share, and revenue. As time goes on, I expect this company to be one of the most impressive growth stories in med-tech, and a stock well worth owning.

PINPOINTing The Opportunity

A lot of Novadaq's future rides on the success of its PINPOINT endoscopic fluorescence imaging system ("Pinpoint"). As the name might suggest, this is an endoscopic system that allows surgeons to visualize anastomoses and perfusion during minimally invasive procedures. Insufficient bloodflow and...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details